FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Knox

Research Profile

Chemicals & Drugs

Disorders

Walker Carcinoma 256

Anatomy

Physiology

Living Beings

Phenomena

Oxidation-Reduction

Concepts & Ideas

Kinetics

Co-author Network

Publications

TOP 3
Longqin Hu; Richard J Knox; Peter F Searle; Simon Oliver Vass; Christopher Bot; Patrick Browne; Lin Chen; Vithurshaa Gobalakrishnapillai; Belinda S Hall; Jiye Han; Xinghua Wu; Shane R Wilkinson
Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Mansooreh Jaberipour; Simon Oliver Vass; Christopher Guise; Jane I Grove; Richard J Knox; Longqin Hu; Eva I Hyde; Peter F Searle
Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Richard J Knox; Philip J Burke; Shiuan Chen; David J Kerr
CB 1954: from the Walker tumor to NQO2 and VDEPT.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Knox (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Longqin Hu; Richard J Knox; Peter F Searle; Simon Oliver Vass; Christopher Bot; Patrick Browne; Lin Chen; Vithurshaa Gobalakrishnapillai; Belinda S Hall; Jiye Han; Xinghua Wu; Shane R Wilkinson
Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Bioorganic & medicinal chemistry letters 2011;21(13):3986-91.
2010: Mansooreh Jaberipour; Simon Oliver Vass; Christopher Guise; Jane I Grove; Richard J Knox; Longqin Hu; Eva I Hyde; Peter F Searle
Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Biochemical pharmacology 2010;79(2):102-11.
2003: Richard J Knox; Philip J Burke; Shiuan Chen; David J Kerr
CB 1954: from the Walker tumor to NQO2 and VDEPT.
Current pharmaceutical design 2003;9(26):2091-104.
2001: SM Bailey; AD Lewis; L H Patterson; G R Fisher; Richard J Knox; P Workman
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species.
Biochemical pharmacology 2001;62(4):461-8.
2000: Richard J Knox; T C Jenkins; S M Hobbs; Shiuan Chen; RG Melton; Philip J Burke
Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Cancer research 2000;60(15):4179-86.
1999: Kenneth D Bagshawe; S K Sharma; Philip J Burke; RG Melton; Richard J Knox
Developments with targeted enzymes in cancer therapy.
Current opinion in immunology 1999;11(5):579-83.
1999: D Anderson; David R Ferry; Richard J Knox; S J Andrews; A J Downes; David J Kerr; Leonard W Seymour
High-performance liquid chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 1999;731(2):293-8.
1999: Kenneth D Bagshawe; Philip J Burke; Richard J Knox; RG Melton; S K Sharma
Targeting enzymes to cancers--new developments.
Expert opinion on investigational drugs 1999;8(2):161-72.
1998: SM Bailey; AD Lewis; Richard J Knox; L H Patterson; G R Fisher; P Workman
Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites.
Biochemical pharmacology 1998;56(5):613-21.
1997: Nicola K Green; D J Youngs; J P Neoptolemos; Frank Friedlos; Richard J Knox; Caroline J Springer; Gill M Anlezark; N Paul Michael; RG Melton; MJ Ford; Lawrence S Young; David J Kerr; Peter F Searle
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Cancer gene therapy 1997;4(4):229-38.
1997: SM Bailey; M D Wyatt; Frank Friedlos; J A Hartley; Richard J Knox; AD Lewis; P Workman
Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
British journal of cancer 1997;76(12):1596-603.
1996: S M Bailey; Richard J Knox; S M Hobbs; T C Jenkins; A B Mauger; R G Melton; P J Burke; T A Connors; Ian R Hart
Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Gene therapy 1996;3(12):1143-50.
1995: J A Bridgewater; Caroline J Springer; Richard J Knox; Nigel P Minton; N P Michael; Mary K Collins
Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2362-70.
1995: T A Connors; Richard J Knox
Prodrugs in cancer chemotherapy.
Stem cells (Dayton, Ohio) 1995;13(5):501-11.
1995: G M Anlezark; R G Melton; R F Sherwood; W R Wilson; W A Denny; Brian Palmer; Richard J Knox; Frank Friedlos; A Williams
Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
Biochemical pharmacology 1995;50(5):609-18.
1995: T A Connors; Ruth Duncan; Richard J Knox
The chemotherapy of colon cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(7-8):1373-8.
1995: Richard J Knox; Frank Friedlos; Michael Jarman; L C Davies; P Goddard; G M Anlezark; R G Melton; R F Sherwood
Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT).
Biochemical pharmacology 1995;49(11):1641-7.
1994: A B Mauger; P J Burke; H H Somani; Frank Friedlos; Richard J Knox
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
Journal of medicinal chemistry 1994;37(21):3452-8.
1994: J V Skelly; P J Collins; Richard J Knox; G M Anlezark; R G Melton
Crystallization and preliminary crystallographic data for an FMN-dependent nitroreductase from Escherichia coli B.
Journal of molecular biology 1994;238(5):852-3.
1993: Richard J Knox; Frank Friedlos; P J Biggs; W D Flitter; M Gaskell; P Goddard; L Davies; Michael Jarman
Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954.
Biochemical pharmacology 1993;46(5):797-803.
1993: Richard J Knox; Frank Friedlos; M P Boland
The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
Cancer metastasis reviews 1993;12(2):195-212.
1992: Richard J Knox; Frank Friedlos; R F Sherwood; R G Melton; G M Anlezark
The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.
Biochemical pharmacology 1992;44(12):2297-301.
1992: G M Anlezark; R G Melton; R F Sherwood; B Coles; Frank Friedlos; Richard J Knox
The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).
Biochemical pharmacology 1992;44(12):2289-95.
1992: Frank Friedlos; P J Biggs; J A Abrahamson; Richard J Knox
Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity.
Biochemical pharmacology 1992;44(9):1739-43.
1992: Frank Friedlos; Richard J Knox
Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system.
Biochemical pharmacology 1992;44(4):631-5.
1992: Frank Friedlos; Michael Jarman; L C Davies; M P Boland; Richard J Knox
Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2).
Biochemical pharmacology 1992;44(1):25-31.
1992: Frank Friedlos; J Quinn; Richard J Knox; J J Roberts
The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink.
Biochemical pharmacology 1992;43(6):1249-54.
1991: Richard J Knox; D A Lydall; Frank Friedlos; C Basham; C J Rawlings; J J Roberts
The Walker 256 carcinoma: a cell type inherently sensitive only to those difunctional agents that can form DNA interstrand crosslinks.
Mutation research 1991;255(3):227-40.
1991: Richard J Knox; Frank Friedlos; T Marchbank; J J Roberts
Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species.
Biochemical pharmacology 1991;42(9):1691-7.
1991: M P Boland; Richard J Knox; J J Roberts
The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)
Biochemical pharmacology 1991;41(6-7):867-75.
1991: Michael J Tilby; C Johnson; Richard J Knox; J Cordell; J J Roberts; C J Dean
Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Cancer research 1991;51(1):123-9.
1989: J J Roberts; T Marchbank; V P Kotsaki-Kovatsi; M P Boland; Frank Friedlos; Richard J Knox
Caffeine, aminoimidazolecarboxamide and dicoumarol, inhibitors of NAD(P)H dehydrogenase (quinone) (DT diaphorase), prevent both the cytotoxicity and DNA interstrand crosslinking produced by 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) in Walker cells.
Biochemical pharmacology 1989;38(22):4137-43.
1989: J V Skelly; D A Suter; Richard J Knox; E Garman; D I Stuart; Mark R Sanderson; J J Roberts; Stephen Neidle
Preliminary crystallographic data for NAD(P)H quinone reductase isolated from the Walker 256 rat carcinoma cell line.
Journal of molecular biology 1989;205(3):623-4.
1988: Richard J Knox; Frank Friedlos; Michael Jarman; J J Roberts
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Biochemical pharmacology 1988;37(24):4661-9.
1988: Richard J Knox; M P Boland; Frank Friedlos; B Coles; C Southan; J J Roberts
The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).
Biochemical pharmacology 1988;37(24):4671-7.
1986: J J Roberts; Frank Friedlos; Richard J Knox
CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells.
Biochemical and biophysical research communications 1986;140(3):1073-8.
1986: Richard J Knox; Frank Friedlos; D A Lydall; J J Roberts
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Cancer research 1986;46(4 Pt 2):1972-9.